USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer
- 3 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 27 (11), 3131-3145
- https://doi.org/10.1038/s41418-020-0568-2
Abstract
Estrogen receptor α (ERα) is the crucial factor in ERα-positive breast cancer progression. Endocrine therapies targeting ERα signaling is one of the widely used therapeutic strategies for breast cancer. However, a large number of the patients become refractory to therapy. Abnormal expression of ERα co-regulator facilitates breast cancer development and tendency of endocrine resistance. Thus, it is necessary to discover the novel co-regulators modulating ERα action. Here, we demonstrate that histone deubiquitinase USP22 is highly expressed in breast cancer samples compared with that in the benign tissue, and high expression of USP22 was significantly associated with poorer overall survival in BCa samples. Moreover, USP22 associates with ERα to be involved in maintenance of ERα stability. USP22 enhances ERα-induced transactivation. We further provide the evidence that USP22 is recruited together with ERα to cis-regulatory elements of ERα target gene. USP22 promotes cell growth even under hypoxia condition and with the treatment of ERα antagonist in breast cancer cells. Importantly, the deubiquitination activity of USP22 is required for its functions on maintenance of ERα stability, thereby enhancing ERα action and conferring endocrine resistance in breast cancer.Keywords
This publication has 43 references indexed in Scilit:
- Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer CellsMolecular Cell, 2017
- Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancerDrug Discovery Today, 2016
- OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cellsOncogene, 2016
- Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancerProceedings of the National Academy of Sciences of the United States of America, 2015
- HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine ResistanceCancer Discovery, 2015
- Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapyNature Reviews Cancer, 2013
- Derailed Estrogen Signaling and Breast Cancer: An Authentic CoupleEndocrine Reviews, 2012
- Cracking the Estrogen Receptor's Posttranslational Code in Breast TumorsEndocrine Reviews, 2011
- MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast CancerCell, 2003
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002